Diagnostic Methods Rankings is a topic within the NeuroWiki knowledge base covering aspects of neurodegenerative disease research and mechanisms. [@amyloid2013]
This page ranks diagnostic methods and biomarkers for neurodegenerative diseases based on clinical utility, validation evidence, accessibility, and disease-modifying potential. [@csf2014]
Diagnostics are evaluated across multiple dimensions: [@datspect2014]
- Sensitivity/Specificity: Accuracy for detecting disease
- Clinical Utility: Impact on patient management
- Evidence Level: Validation in large cohorts
- Accessibility: Availability and cost
- Invasiveness: Patient burden
¶ Tier 1: Highly Validated, Clinically Standard
These methods have strong evidence and are routinely used in clinical practice. [@tau2017]
| Metric | Value | [@blood2021]
|--------|-------| [@alphasynuclein2018]
| Sensitivity | >95% | [@fdgpet2006]
| Specificity | >90% | [@hippocampal2002]
| Clinical Utility | High | [@apoe2010]
| Evidence | Strong | [@digital2020]
Amyloid PET using tracers like florbetapir (Amyvid), flutemetamol (Vizamyl), and florbetaben (Neuraceq) directly visualizes amyloid plaques in the brain 1. It is FDA-approved for dementia evaluation when amyloid etiology is uncertain. [@retinal2015]
| Metric |
Value |
| Sensitivity |
80-90% |
| Specificity |
80-85% |
| Clinical Utility |
High |
| Evidence |
Strong |
Cerebrospinal fluid analysis for amyloid-beta 42, total tau, and phosphorylated tau provides biomarker confirmation of AD pathology 2. These are included in research criteria and increasingly used clinically.
| Metric |
Value |
| Sensitivity |
~90% |
| Specificity |
~80% |
| Clinical Utility |
High |
| Evidence |
Strong |
DaT-SPECT (I123-ioflupane) confirms dopaminergic deficit in parkinsonian syndromes, differentiating PD from essential tremor with high accuracy 3.
These methods have substantial validation but are not yet standard clinical practice.
| Metric |
Value |
| Sensitivity |
90-95% |
| Specificity |
85-90% |
| Clinical Utility |
Moderate-High |
| Evidence |
Growing |
Tau PET (flortaucipir) visualizes neurofibrillary tangle burden and correlates with clinical severity 4. Currently primarily used in research.
| Metric |
Value |
| Sensitivity |
75-90% |
| Specificity |
75-85% |
| Clinical Utility |
High (screening) |
| Evidence |
Growing |
Blood-based tau (p-tau181, p-tau217) and neurofilament light chain (NfL) show promise for screening and disease monitoring 5. Expected to transform clinical practice.
| Metric |
Value |
| Sensitivity |
85-95% |
| Specificity |
90-95% |
| Clinical Utility |
Moderate |
| Evidence |
Growing |
Real-time quaking-induced conversion (RT-QuIC) and protein misfolding cyclic amplification (PMCA) detect pathological alpha-synuclein with high sensitivity 6.
These methods support diagnosis but have limitations.
| Metric |
Value |
| Sensitivity |
75-85% |
| Specificity |
70-80% |
| Clinical Utility |
Moderate |
| Evidence |
Moderate |
FDG-PET shows characteristic hypometabolism patterns (posterior cingulate, precuneus in AD; occipital cortex in DLB; brainstem in PD) 7.
| Metric |
Value |
| Sensitivity |
Variable |
| Specificity |
Moderate |
| Clinical Utility |
High |
| Evidence |
Strong |
MRI assesses regional atrophy patterns, vascular damage, and rules out treatable causes. Hippocampal atrophy is a key AD marker 8.
| Metric |
Value |
| Sensitivity |
N/A |
| Specificity |
N/A |
| Clinical Utility |
High (for specific cases) |
| Evidence |
Strong |
APOE genotyping provides risk information; monogenic testing confirms familial forms. Appropriate for cases with early onset or family history 9.
¶ Tier 4: Emerging and Research-Only
These methods require more validation before clinical adoption.
Wearable sensors, smartphone apps, and voice analysis show promise but lack standardization [10](https://doi.org/10.1001/jama Neurol.2020.2836).
Optical coherence tomography (OCT) measures retinal nerve fiber layer thickness but correlation with brain pathology is still being established 11.
- Amyloid PET or CSF Aβ42 (required for definitive diagnosis)
- CSF p-tau or Tau PET (confirms tau pathology)
- Structural MRI (assesses atrophy, rules out causes)
- FDG-PET (characterizes hypometabolism)
- Blood p-tau (screening, monitoring)
- DaT-SPECT (confirms dopaminergic deficit)
- Clinical criteria (MDS criteria)
- MRI (rules out atypical parkinsonism)
- Alpha-synuclein RT-QuIC (confirms synucleinopathy)
- Smell test (prodromal detection)
- EMG (confirms motor neuron involvement)
- Neurofilament biomarkers (NfL, pNfH) - prognostic
- Genetic testing (C9orf72, SOD1, FUS)
- MRI (rules out mimics)
- MRI biomarkers - Midbrain and superior cerebellar peduncle atrophy (hummingbird sign), morning glory sign, third ventricle enlargement [@mri2012]
- Tau PET (flortaucipir) - Binding to tau pathology in PSP subcortical regions [@tau2020]
- DaT-SPECT - Shows reduced dopamine transporter binding in striatum (less pronounced than in PD)
- Clinical criteria - MDS-PSP criteria incorporating oculomotor, postural, and gait abnormalities [@mdspsp2017]
- CSF biomarkers - Elevated total tau and p-tau181; lower Aβ42 compared to controls [@csf2022]
- FDG-PET - Characteristic midbrain and frontal hypometabolism pattern [@fdgpet2013]
- Blood biomarkers - NfL elevated in PSP vs. PD; p-tau217 shows promise [@blood2022]
- Richardson syndrome (PSP-RS): Classic presentation - oculomotor palsy, postural instability, vertical supranuclear gaze palsy
- PSP with parkinsonism (PSP-P): Treated as PD initially, less oculomotor involvement
- Cortical basal syndrome presentation (CBS-PSP): Asymmetric apraxia, cortical sensory loss
- MRI biomarkers - Asymmetric cortical atrophy (parietal, frontal), contralateral to most symptoms [@mri2005]
- Tau PET (flortaucipir) - Shows tau deposition in cortical and subcortical regions
- DaT-SPECT - Dopaminergic deficit present, helps differentiate from PSP
- Clinical criteria - Armstrong criteria for probable CBS [@armstrong2013]
- FDG-PET - Asymmetric hypometabolism in affected cortical regions
- CSF biomarkers - Similar to PSP with elevated tau; may show distinct profiles
- Blood biomarkers - NfL elevated; p-tau217 promising
- Cortical signs: Apraxia, alien limb, cortical sensory loss favor CBS
- Oculomotor: Vertical supranuclear gaze palsy favors PSP
- Symmetry: CBS typically asymmetric; PSP usually symmetric
- MRI: Asymmetric atrophy favors CBS; midbrain atrophy favors PSP
- Blood biomarkers will likely become first-line screening
- Multimodal approaches combining biomarkers and digital data
- Integration of AI for pattern recognition (e.g., AIDP diffusion MRI + SVM)
- Point-of-care testing for accessible diagnostics
The following conditions lack dedicated diagnostic rankings:
- Progressive Supranuclear Palsy (PSP): See disease-specific rankings above
- Corticobasal Syndrome (CBS): See disease-specific rankings above
- Multiple System Atrophy (MSA): No dedicated ranking
- Dementia with Lewy Bodies (DLB): Only mentioned in FDG-PET section, no dedicated ranking
- Frontotemporal Dementia (FTD): No dedicated ranking
- Huntington's Disease: No dedicated ranking
- Vascular Dementia: No dedicated ranking
- Genetic testing: Only APOE and monogenic testing covered - missing polygenic risk scores, carrier screening
- Digital biomarkers: Only mentioned in Tier 4 - no specific rankings or comparisons
- Retinal imaging: Only mentioned in Tier 4 - missing specific biomarkers (RNFL, GCL thickness)
- Olfactory testing: Only mentioned in PD - not systematically ranked
- Skin biopsy: Alpha-synuclein detection in cutaneous nerves - emerging but not ranked
- Muscle biopsy: Useful in certain myopathies and metabolic disorders
- Transcranial magnetic stimulation (TMS): Motor and cognitive measures for differential diagnosis
- Autonomic testing: Important for MSA, PD, DLB differentiation
- Sleep studies: REM sleep behavior disorder detection for synucleinopathies
- Neurofilament light chain (NfL): Mentioned in ALS but not systematically ranked across diseases
- Neurogranin: Synaptic biomarker - mentioned in AD research but not ranked
- YKL-40: Microglial activation marker - not covered
- Alpha-synuclein blood tests: Emerging assays not yet ranked
- Unknown, Amyloid PET for AD (2013) (2013)
- Unknown, CSF biomarkers for AD (2014) (2014)
- Unknown, DaT-SPECT in parkinsonism (2014) (2014)
- Unknown, Tau PET imaging (2017) (2017)
- Unknown, Blood biomarkers for AD (2021) (2021)
- Unknown, Alpha-synuclein RT-QuIC (2018) (2018)
- Unknown, FDG-PET in dementia (2006) (2006)
- Unknown, Hippocampal atrophy MRI (2002) (2002)
- Unknown, APOE and AD risk (2010) (2010)
DOI:10.1001/jama
- Unknown, Retinal imaging in neurodegeneration (2015) (2015)
- Unknown, MRI in PSP (2012) (2012)
- Unknown, Tau PET in PSP (2020) (2020)
- Unknown, MDS-PSP criteria (2017) (2017)
- Unknown, CSF biomarkers in PSP (2022) (2022)
- Unknown, FDG-PET in PSP (2013) (2013)
- Unknown, Blood biomarkers in PSP (2022) (2022)
- Unknown, MRI in CBS (2005) (2005)
- Unknown, Armstrong CBS criteria (2013) (2013)